Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (5): 739-744    DOI: 10.31083/j.ejgo.2020.05.2116
Original Research Previous articles | Next articles
The Role of Akt2 and CA-125 Serum Levels as Predictors for Successful Cytoreduction in Epithelial Ovarian Cancer Surgery
Yudi Mulyana Hidayat1, Gatot Nyarumenteng Adhipurnawan Winarno1, Maringan Diapari Lumban Tobing1, Arieff Kustiandi1, Kemala Isnainiasih Mantilidewi1, *(), Sofie Rifayani Krisnadi1
1Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran-Dr Hasan Sadikin General Hospital, Jl. Pasteur No. 38, Bandung 40161, West Java, Indonesia
Download:  PDF(261KB)  ( 87 ) Full text   ( 5 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Ovarian cancer is one of the common causes of cancer deaths in gynecological malignancies in Indonesia, and indeed the world. Of all classifications of ovarian cancer, the epithelial subtype shows the highest incidence. Cytoreductive surgery is a determinant of prognosis for patients with advanced epithelial ovarian cancer. One possible way to predict the results of cytoreductive surgery is to measure preoperative tumor marker levels. This study aimed to assess the validity of serum levels of Protein kinase Bβ (Akt2) and cancer antigen-125 (CA-125) as outcome predictors for cytoreduction in epithelial ovarian cancer surgery. This was an observational, analytical, cross-sectional study. Akt2 and CA-125 serum levels were examined by enzyme-linked immunosorbent assay (ELISA) and immunoassay technique, respectively. Mean levels of Akt2 and CA-125 were significantly different between optimal and suboptimal cytoreduction groups (p < 0.05). The cut-off point (COP) value obtained for Akt2 was 1.20 U/mL with area under curve (AUC) value of 68.9%, while the COP for CA-125 was 222.50 U/mL with AUC value of 75.3 % (p < 0.05). If the preoperative Akt2 serum level was greater than 1.20 U/mL, and preoperative CA-125 level was greater than 222.5 U/mL, the probability of suboptimal cytoreduction was increased. Thus, our study highlights the possibility for Akt2 and CA-125 levels to be used as serum biomarkers in predicting the success of cytoreductive surgery.
Key words:  Epithelial ovarian cancer      Cytoreduction      Akt2      CA-125     
Submitted:  27 December 2019      Accepted:  17 June 2019      Published:  15 October 2020     
Fund: 
06/E/KPT/2019(INSINAS)/Ministry of Research, Technology and Higher Education of the Republic of Indonesia
*Corresponding Author(s):  KEMALA ISNAINIASIH MANTILIDEWI     E-mail:  kmantilidewi@gmail.com

Cite this article: 

Yudi Mulyana Hidayat, Gatot Nyarumenteng Adhipurnawan Winarno, Maringan Diapari Lumban Tobing, Arieff Kustiandi, Kemala Isnainiasih Mantilidewi, Sofie Rifayani Krisnadi. The Role of Akt2 and CA-125 Serum Levels as Predictors for Successful Cytoreduction in Epithelial Ovarian Cancer Surgery. European Journal of Gynaecological Oncology, 2020, 41(5): 739-744.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.05.2116     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I5/739

[1] Lingyun Zhai, Lixin Zeng, Hongru Jiang, Wei Li. Effects of a cyclooxygenase-1-selective inhibitor in combination with taxol or cisplatin on cyclin D1, apoptosis, and vascular endothelial growth factor in a xenograft model of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 779-784.
[2] Gen-Hai Zhu, Kang Wang, Lan Hong, Xin-Hui Fu, Fu-Jin Liu, Hai-Yan Huang. Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 609-616.
[3] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[4] Emine Karabuk, Burak Karadag, Ceyda Karadag, M. Faruk Kose, M. Murat Naki, E. Nilufer Guler. The outcomes of fertility sparing surgery in epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 391-395.
[5] Can Fang, Yan Zhao, Kezhen Li, Danhui Weng, Peng Wu, Gang Chen, Ding Ma, Juncheng Wei. Diabetes mellitus and epithelial ovarian cancer in Chinese women: a retrospective cohort study[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 260-264.
[6] X.Z. Cheng, Z. Zhou, M.Y. Yang, Y.L. Cai, F. Deng, X.X. Chen. Prognostic factors for types I and II epithelial ovarian cancer in the elderly[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 7-15.
[7] J. Liang, X. Yang, L. Liu, L. Qiao, P. Peng, J. Zhou. Combined measurement of miRNA-183, HE4, and CA-125 increases diagnostic efficiency for ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 30-35.
[8] V. Pažin, A. Dobrosavljevic, L. Nejkovic. Primary fallopian tube carcinoma - case report[J]. European Journal of Gynaecological Oncology, 2019, 40(1): 163-165.
[9] Chen Mi, Cancan Zhang, Qi Zhang, Aiyun Xing. Increased expression of lncRNA HULC in human epithelial ovarian cancer and its biological functions[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 992-996.
[10] Jing Zhao, Xue Dong, Qing-cui Liu, Qun Lu. Expression of plasma miR-106a in epithelial ovarian cancer and its diagnostic and prognostic significance[J]. European Journal of Gynaecological Oncology, 2018, 39(5): 769-772.
[11] Li-Yuan Guo, San-Yuan Zhang, Chen Chen, Hao-Xia Zeng, Feng-Yan Li, Qiu-Xiang Xu. Lentinan combined with cisplatin and paclitaxel in the treatment of patients with ovarian cancer with ascites[J]. European Journal of Gynaecological Oncology, 2018, 39(4): 615-620.
[12] K. Yao, C. Bian, L. Li, Y. Wu, X. Zhao. The clinical response of advanced epithelial ovarian cancer patients to neoadjuvant chemotherapy in China[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 377-380.
[13] C.M. Sepúlveda-Rivera, S.A. Barquet-Muñoz, C. Pérez-Plascencia, R. Salcedo-Hernández, A.M. Ruiz-Beltrán, D. Cantú de León. Is adjuvant treatment in early-stage uterine sarcomas beneficial?[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 443-447.
[14] Jun Zhu, Hao Wen, Rui Bi, Xiaohua Wu. A retrospective study of clinicopathological characteristics, treatment, and outcomes of Chinese uterine and ovarian carcinosarcoma patients[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 448-453.
[15] Rania Mohamed ElSharkawy, Fady M. Shawky Moiety. Evaluation of CA-125, CA72-4, HE-4, and M-CSF as early diagnostic markers for ovarian cancer in Egyptian women[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 454-457.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] Akanksha Agrawal, Deepanshu Jain, Pradhum Ram, Jorge Luis Penalver Leon, Janani Rangaswami. Anticoagulation for intra-cardiac thrombi in peripartum cardiomyopathy: A review of the literature[J]. Reviews in Cardiovascular Medicine, 2019, 20(2): 53 -58 .
[3] B. Soltész, J. Lukács, A. Penyige, R. Póka, B. Nagy. Determination of miR-193b rs30236 single nucleotide polymorphism in ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 547 -550 .
[4] Y. Li, C. Li, N. Li, L. Jiang, W. Yang, Y. Wang, B. Wu, C. Shi, Z. Zhu. RNAi silenced NUP88 gene suppresses growth and invasiveness of human breast cancer cell line MCF-7[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 634 -639 .
[5] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .
[6] T. Tomimatsu, S. Mabuchi, T. Tsuboyama, Y. Hori, S. Sekine, T. Kimura. Malignant transformation of uterine leiomyoma: suggested by clinical, imaging, histological, and genetic findings[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 879 -882 .
[7] Z. Protrka, P. Arsenijevic, N. Jovic, S. Zivanovic, J. Djuric, A. Dimitrijevic. A case of uterine torsion in term pregnancy associated with placental abruption and intrauterine fetal demise[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 287 -289 .
[8] T. Ueno, H. Yabushita, K. Iwasaki, A. Wakatsuki. Role of adiponectin and leptin in non-diabetic, non-obese patients with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 199 -204 .
[9] P. Pimsi, W. Santimaleeworagun, S. Therasakvichya, N. Saengsukkasemsak, A. Laocharoenkeat. The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 242 -246 .
[10] F. Lai-Tiong. Dermatomyositis revealing a 18-year breast cancer recurrence[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 292 -293 .